Private Asset Management Decreased Wells Fargo Company (WFC) Holding By $174.15 Million; Concert Pharmaceuticals, Inc. (CNCE) Had 9 Bulls

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals had 24 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, September 18. The stock has “Buy” rating by Brean Capital on Wednesday, August 12. Aegis Capital initiated the stock with “Buy” rating in Wednesday, September 9 report. The rating was maintained by H.C. Wainwright on Friday, March 2 with “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Friday, July 1. The company was maintained on Monday, November 6 by Mizuho. Mizuho upgraded Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) rating on Friday, March 9. Mizuho has “Buy” rating and $27.0 target. Aegis Capital maintained the stock with “Buy” rating in Thursday, June 29 report. Roth Capital maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Tuesday, September 22 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Friday, November 10. See Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) latest ratings:

09/03/2018 Broker: Mizuho Rating: Buy New Target: $27.0 Upgrade
02/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $21 New Target: $25 Maintain
12/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $27.0 Maintain
12/01/2018 Broker: Mizuho Old Rating: Buy New Rating: Neutral Old Target: $23 New Target: $23 Downgrade
19/12/2017 Broker: UBS Rating: Buy New Target: $34.0 Maintain
10/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $21.0 Maintain
06/11/2017 Broker: Mizuho Rating: Buy New Target: $23.0 Maintain
26/10/2017 Broker: Mizuho Rating: Buy New Target: $23 Initiates Coverage On
19/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $30.0 Maintain
20/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $21.0 Maintain

Private Asset Management Inc decreased Wells Fargo Company (WFC) stake by 94.9% reported in 2017Q3 SEC filing. Private Asset Management Inc sold 174,145 shares as Wells Fargo Company (WFC)’s stock declined 8.66%. The Private Asset Management Inc holds 9,363 shares with $9.36 million value, down from 183,508 last quarter. Wells Fargo Company now has $272.57 billion valuation. The stock decreased 1.64% or $0.93 during the last trading session, reaching $55.9. About 37.10 million shares traded or 68.83% up from the average. Wells Fargo & Company (NYSE:WFC) has risen 9.67% since March 19, 2017 and is uptrending. It has underperformed by 7.03% the S&P500.

Analysts await Wells Fargo & Company (NYSE:WFC) to report earnings on April, 12. They expect $1.07 EPS, up 7.00% or $0.07 from last year’s $1 per share. WFC’s profit will be $5.22 billion for 13.06 P/E if the $1.07 EPS becomes a reality. After $0.97 actual EPS reported by Wells Fargo & Company for the previous quarter, Wall Street now forecasts 10.31% EPS growth.

Among 39 analysts covering Wells Fargo & Company (NYSE:WFC), 15 have Buy rating, 8 Sell and 16 Hold. Therefore 38% are positive. Wells Fargo & Company has $76 highest and $44 lowest target. $59.88’s average target is 7.12% above currents $55.9 stock price. Wells Fargo & Company had 131 analyst reports since July 29, 2015 according to SRatingsIntel. On Tuesday, January 12 the stock rating was upgraded by Keefe Bruyette & Woods to “Outperform”. The firm earned “Mkt Perform” rating on Wednesday, October 19 by FBR Capital. The rating was downgraded by Keefe Bruyette & Woods on Monday, February 5 to “Hold”. Keefe Bruyette & Woods maintained the stock with “Buy” rating in Thursday, September 28 report. The firm has “Sell” rating given on Thursday, March 24 by UBS. As per Sunday, February 4, the company rating was maintained by BMO Capital Markets. The rating was maintained by Raymond James on Tuesday, August 8 with “Sell”. The stock has “Hold” rating by Citigroup on Monday, February 5. The rating was maintained by BMO Capital Markets on Thursday, January 4 with “Hold”. The firm earned “Buy” rating on Monday, November 13 by RBC Capital Markets.

Investors sentiment increased to 0.75 in Q3 2017. Its up 0.02, from 0.73 in 2017Q2. It increased, as 92 investors sold WFC shares while 725 reduced holdings. 103 funds opened positions while 495 raised stakes. 3.65 billion shares or 0.40% less from 3.66 billion shares in 2017Q2 were reported. Meiji Yasuda Asset Management Limited, Japan-based fund reported 179,790 shares. The Tennessee-based Patten And Patten Tn has invested 0.74% in Wells Fargo & Company (NYSE:WFC). State Farm Mutual Automobile Ins holds 4.07% or 55.04M shares in its portfolio. Mark Sheptoff Finance Planning Ltd owns 0.26% invested in Wells Fargo & Company (NYSE:WFC) for 7,040 shares. Butensky Cohen Fin Security holds 40,365 shares. 1.85M were reported by Dekabank Deutsche Girozentrale. Moody State Bank Trust Division reported 31,953 shares. Jnba holds 14,843 shares. Principal Fin Group Incorporated has 10.30 million shares. First State Bank Of Omaha reported 0.95% in Wells Fargo & Company (NYSE:WFC). Nordea Invest Ab accumulated 5.93 million shares. Voya Invest Management Limited Liability Company owns 5.63 million shares or 0.67% of their US portfolio. Asset Mgmt One Limited has 7.64 million shares for 0.99% of their portfolio. Trillium Asset Mgmt Ltd has invested 0.01% of its portfolio in Wells Fargo & Company (NYSE:WFC). Palisade Asset Management has 241,080 shares.

Since November 17, 2017, it had 0 buys, and 1 sale for $292,234 activity. Codel Franklin R sold 5,393 shares worth $292,234.

Investors sentiment increased to 2.62 in Q3 2017. Its up 1.44, from 1.18 in 2017Q2. It increased, as 13 investors sold Concert Pharmaceuticals, Inc. shares while 20 reduced holdings. 17 funds opened positions while 22 raised stakes. 14.57 million shares or 5.31% more from 13.83 million shares in 2017Q2 were reported. Legal & General Gru Public Limited Co owns 5,414 shares or 0% of their US portfolio. Balyasny Asset Mngmt Lc reported 0% stake. Deutsche Financial Bank Ag holds 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 21,012 shares. 130,602 are held by Geode Cap Mgmt Ltd. 228 are held by Meeder Asset Management. Principal has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Prelude Capital Mgmt Ltd Liability Com holds 0% or 700 shares. Qs Investors Lc holds 91,262 shares. California State Teachers Retirement Sys owns 28,469 shares for 0% of their portfolio. Prudential accumulated 64,910 shares or 0% of the stock. Illinois-based Citadel Advisors Ltd Company has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 20,448 are held by Rhumbline Advisers. 314,842 are owned by State Street. Senzar Asset Management accumulated 335,445 shares.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $530.18 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 5.62 P/E ratio. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

The stock increased 1.60% or $0.36 during the last trading session, reaching $22.82. About 248,667 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 18.70% since March 19, 2017 and is uptrending. It has outperformed by 2.00% the S&P500.